Paper Digest: AACR 2026 Papers & Highlights

The American Association for Cancer Research Annual Meeting (AACR) is among the world’s premier cancer research forums. For the 2026 meeting in San Diego, the program includes over 6,000 accepted papers across 200 specialized areas. To facilitate rapid literature review, the Paper Digest Team has processed and indexed all accepted papers by research area. This integration allows the healthcare community to quickly browse papers by specific area, search & review papers by topic, follow papers by author, and connect each paper to the broader related literature.

Since 2018, Paper Digest has built a foundation of data spanning decades of conferences, journals, and research topics. The platform features a daily digest service that sifts through tens of thousands of new papers, clinical trials, news articles, and community posts, filtering the noise to highlight what matters most to specific interests. Beyond daily updates, dozens of built-in research tools streamline the academic workflow, supporting efficient reading and writing, comprehensive literature reviews, and automated research report generation.

AACR-2026 Papers by Area
1, AACR Project GENIE: Genomic Characterization
2, AACR Project GENIE: Predictive Models and AI
3, Adaptive Immunity in Cancer
4, Adoptive Cell Therapy
5, Advances in Survivorship
6, Agentic AI in Cancer
7, Aging and Host Determinants of Tumor Progression: The Macroenvironmental Axis
8, Alternative Cell Type and in Situ Cell Therapies
9, Angiogenesis
10, Antibodies, Antibody-Drug Conjugates, and Nucleic Acids
11, Antibody Technologies and Platforms
12, Antibody-Drug Conjugates
13, Antibody-Drug Conjugates and Linker Engineering
14, Application of Bioinformatics to Cancer Biology
15, Bi- and Tri-Specific Antibody Therapies
16, Biological Mechanisms of Tumor and Normal Tissue Response and Clinical Studies
17, Biological and Clinical Consequences of Cancer Therapy
18, Biomarkers Predictive of Therapeutic Benefit
19, Biomarkers of Endogenous or Exogenous Exposures, Early Detection, Biological Effects, and Prognosis
20, Biostatistics in Clinical Trials / Surgical Oncology
21, CAR T Cell Functional Enhancement
22, CAR T Cell Targets and TME Reprogramming
23, Cancer Disparities
24, Cancer Surveillance: Emerging Cancer Trends and Population Differences
25, Cancer and Aging: Implications for Outcomes
26, Cancer and Cancer Related Alterations, Detection Approaches, and Molecular Characterization
27, Cancer in the Community: Epidemiology, Experimental Knowledge, Action, and Communication
28, Cell Cycle
29, Cell Death Pathways and Treatment
30, Cell Death Regulation and Therapeutic Resistance in Cancer
31, Cellular Responses to Anticancer Drugs
32, Characterization of Metastases by Imaging and Profiling
33, Chromatin Architecture and Regulatory Landscapes
34, Chromatin Structure and Function
35, Circulating Tumor Cells, Metastasis, and Dissemination Biology
36, Clinical Correlates of Immunotherapy
37, Combination Immunotherapies
38, Combination Targeted Therapy
39, Community-Engaged Approaches to Equity Across the Cancer Journey: From Prevention to Trial Design
40, Computational, Technological, and Mechanistic Advances
41, Contextual Determinants of Cancer Stemness and Tumor Aggressiveness
42, DNA Damage and Repair
43, DNA Methylation
44, Data-Driven Approaches to Precision Oncology
45, Deep Learning in Cancer
46, Developmental Origins, Drivers, and Heterogeneity in Pediatric Cancer
47, Diagnostic Biomarkers
48, Diet, Alcohol, and Tobacco, and Other Lifestyle Factors
49, Digital Pathology
50, Drug Combinations, Repurposing, and Differentiation
51, Drug Delivery
52, Drug Resistance: Antibodies and ADCs
53, Drug Resistance: Tyrosine Kinase Inhibitors
54, Early Detection Biomarkers
55, Early Detection and Interception
56, Effects of Ionizing Radiation on Normal Tissues and FLASH Radiation Research
57, Engineering the Next Wave of Antibody-Based Cancer Therapeutics
58, Environmental and Occupational Risk Factors, Infection, and Aging
59, Epidemiology: Cancer Incidence, Mortality, Patterns, and Methodology
60, Epigenetic Changes as Molecular Markers of Cancer
61, Epigenetic Modulators
62, Epigenetics, Cytogenetics, and Clinical Molecular Genetics
63, Epigenomics
64, Epithelial-to-Mesenchymal Transition
65, Etiology and Molecular Epidemiology Approaches to Decipher Cancer Disparities
66, Ex Vivo Systems: Patient-Derived, Patient-Specific Tumor Cultures
67, Experimental Chemoprevention and Interception: Data and Tools
68, Extracellular Vesicles and Long-Range Tumor-Host Communication
69, Fibroblasts as Architects of the Tumor Microenvironment
70, Functional Roles of Noncoding RNAs in Cancer Progression, Metabolism, and Therapy Response
71, Functional and Spatial Regulation of Immune Evasion and Anti-Tumor Immunity
72, Gene and Vector-Based Therapy
73, Genetic Epidemiology: GxE, GWAS, Polygenic Risk Scores, and Post-GWAS
74, Genetic Epidemiology: Pathway Analysis, Sequencing, Functional Genetics / Family and Hereditary Studies
75, Genetic and Transcriptomic Dissection of Cancer Evolution
76, Genomic Approaches to Define Tumor Biology and Clinical Stratification
77, Genomic Dissection to Define Novel Therapeutic Strategies
78, Genomic Drivers of Cancer Pathogenesis
79, Genomic Profiling to Understand Cancer Biology
80, Genomics, Proteomics, Biomarkers, and Risk Stratification
81, Hematologic Malignancies and Novel Therapeutic Modalities
82, High-Dimensional Immune Profiling and Preclinical Modeling for Cancer Immunotherapy
83, Hormone Receptor Signaling and Therapeutic Targeting
84, Humanized Mouse Models
85, Hypoxic and Proteotoxic Stress Response
86, Immune Cell Biology and Tumor-Immune Crosstalk
87, Immune Checkpoint Blockade
88, Immune Checkpoints
89, Immune Mechanisms Invoked by Other Therapies and Exposures
90, Immune Response to Therapies
91, Immunomodulatory Agents
92, Immunomodulatory Agents and Interventions
93, Immunomodulatory Effects of Targeted Therapies
94, Immunotherapies in Pediatric Cancers
95, In Vitro Models: 2D and 3D
96, In Vitro Models: 2D, 3D, Organoids, and Spheroids
97, In Vivo Imaging
98, In Vivo Models: Genetically Engineered Mouse Models, PDXs, Syngeneic Models
99, In Vivo Models: Mouse, Zebrafish, and Alternative Species
100, Inflammation and Cancer Progression
101, Inflammation, Immunity, and Cancer
102, Innate Immunity in Cancer
103, Innovative Therapeutic Modalities and Translational Platforms
104, Insights into Genomic Instability
105, Integration of Clinical and Research Data
106, Integrative Computational Approaches
107, Kinase and Signaling Pathway Dependencies Driving Cancer Therapeutic Response
108, Large Language Models in the Clinic
109, Liquid Biopsies: Circulating Nucleic Acids
110, Liquid Biopsy: Multi-Analyte and Multi-Omic
111, Machine Learning Approaches for Cancer Prediction
112, Machine Learning for Image Analysis
113, Mathematical Modeling and Statistical Methods
114, Mechanism-Guided Development of Targeted Cancer Therapies
115, Mechanisms and Dynamics of Gene Expression
116, Mechanisms and Targets in DNA Damage Repair
117, Mechanisms of Anticancer Drug Action
118, Mechanisms of Drug Resistance
119, Mechanisms of Metastasis
120, Mechanistic Insights for Targeted Therapies in Pediatric Cancer
121, Metabolic Alterations in Colorectal and Gastrointestinal Cancers
122, Metabolic Features of Thoracic and Urologic Cancers
123, Metabolic Regulation in Breast and Gynecologic Cancers
124, Metabolic Studies in Brain, Pediatric, and Hematologic Cancers
125, Metabolic Vulnerabilities in Pancreatic, Hepatic, and Renal Cancers
126, Metabolic and Transcriptional Control of Cancer Stem Cell Plasticity
127, Metabolism and Microbiome in Cancer Initiation and Prevention
128, Metabolite Control of Chromatin, Redox, and Cellular Stress Responses
129, Metastasis and Organ-Specific Microenvironmental Evolution
130, Metastatic Niches and Microenvironment
131, Methods to Measure Tumor Evolution and Heterogeneity
132, MicroRNAs as Cancer Biomarkers, Therapeutic Targets, and Modulators of Treatment Response
133, Microbiome, Inflammation, and Response to Immunotherapy in Cancer
134, Microbiome-Tumor-Immune Crosstalk
135, Microenvironmental Determinants of Therapy Response and Resistance
136, Migration and Invasion
137, Modifiers of Inflammation and the Tumor Microenvironment
138, Molecular Classification and Tumor Biology in Cancer
139, Molecular Imaging, Radiomics, and Theranostics
140, Molecular Pathology
141, Molecular Targeted Therapy
142, Molecular Targets
143, Monoclonal Antibodies and Antibody-Cytokine Platforms
144, Multi-Axis Antineoplastic Agents
145, Multi-Omics, Systems Biology, and Biological Mass Spectrometry
146, Nanocarriers and Drug Delivery Systems
147, Natural Products
148, Network Biology and Precision Medicine
149, New Algorithms and Computational Methods
150, New Ligands and Inhibitors
151, New Software Tools for Data Analysis
152, Next-Generation Targeted Therapies Directed Against Tumor Surface Antigens
153, Noninvasive Imaging and Analysis of Animal and Tissue Models
154, Novel Antitumor Agents
155, Novel Experimental Platforms and Causal Inference
156, Novel Models of Immunotherapy Response
157, Novel Strategies to Reverse Drug Resistance
158, Novel Targets and Pathways
159, Novel Therapeutics and Drug Targets
160, Oncogenic Pathways and Cancer Immunity
161, Oncogenic Transcription Factors and Cancer Programs
162, Overcoming Chemotherapy Resistance
163, Overcoming Microenvironmental and Delivery Barriers in Cancer Therapy
164, Pediatric Cancer Genomics and Epigenomics
165, Pediatric Cancer Models
166, Pharmacogenomics and Translational Biomarkers for Precision Cancer Therapy
167, Physicochemical Modulation of Cancer Ecosystems: Mechanical Forces, Hypoxia, and Acidosis
168, Precision Oncology and Real World Data
169, Prognostic Biomarkers
170, Proteomics: Biomarker Discovery and Signaling Networks
171, Proximity-Induced Drug Discovery
172, Psychosocial and Behavioral Epidemiology, Health Services Research, Implementation Science, Pharmacoepidemiology, and Other Topics
173, Quantitative Pharmacology and Translational Modeling
174, RAS/MAPK Signaling, KRAS Targeting, and Adaptive Resistance
175, RNA, Gene and Cell Therapies, and Enabling Assay Technologies
176, RTK-ERBB-PI3K and New Targets in Therapeutic Resistance
177, Radiation and Photodynamic Therapy Response Modifiers
178, Radiomics and AI in Medical Imaging
179, Radiopharmacuetical Platforms for Theranostic Precision Oncology
180, Real World Data to Provide Real World Evidence
181, Real World Impact of Prognostic and Predictive Parameters
182, Redefining Targeted Therapy: Bispecific T-Cell Engagers and Antibody-Drug Conjugates
183, Regulatory Science and Policy
184, Retrospective Observational Studies
185, Risk Prediction Modeling, Screening, Early Detection, and Preneoplastic and Tumor Markers
186, Role of the Microenvironment in Therapeutic Response
187, Science and Health Policy
188, Screening and Technology Advances for Probe and Drug Discovery
189, Senescence and Cell Stress
190, Sequence Analysis
191, Signaling Pathways, Metabolism, and Emerging Therapeutic Targets
192, Spatial Niches and Functional Boundaries within the Tumor Microenvironment
193, Spatial Protein Profiling and Multi-Modal Mapping of Tumor and Circulating Ecosystems
194, Spatial Proteomics and Transcriptomics
195, Stem Cell Plasticity and Lineage Reprogramming in Cancer
196, Strategies to Enhance the Therapeutic Index of Radiotherapy
197, Structural and Chemical Biology
198, Survivorship Research
199, Survivorship Research Addressing Cancer Disparities
200, Survivorship, Supportive Care, and Quality of Life in Oncology
201, T Cell Engagers
202, T Cell Engagers / Antibody-Drug Conjugates
203, TCR and Autologous T Cell Therapies
204, Targeted Antigen Therapies and Immunity
205, Targeted Protein Degradation and Induced Proximity
206, Targeted Radiopharmaceuticals and Combination Strategies in Cancer Therapy
207, Targeted Therapies, Predispositions, and Survivorship in Pediatric Cancers
208, Targeting Cell Surface Vulnerabilities to Overcome Therapeutic Resistance
209, Targeting DNA Repair, Cell Cycle, and Tumor Metabolism
210, Targeting Drug Resistance: Apoptosis and Autophagy
211, Targeting Drug Resistance: RAS Signaling
212, Targeting Mitochondria and Metabolic Vulnerabilities for Cancer Therapy
213, Tertiary Lymphoid Structures in Cancer
214, Therapeutic Modulation of the Tumor Microenvironment: New Targets and Approaches
215, Therapies Targeting Metastasis
216, Transcription Factor Function in Cell Identity, Signaling, and Post-Transcriptional Control
217, Translational Biomarkers and Emerging Molecular Approaches
218, Tumor Adhesion
219, Tumor Cell Plasticity, Microenvironment, and Stress-Response Pathways
220, Tumor Diagnostics, Prognostics, and Therapeutic Outcomes
221, Tumor Evolution
222, Tumor Heterogeneity
223, Tumor Microenvironment Modulators
224, Tumor Microenvironment, Multispecifics, and Immunomodulation
225, Tumor Models and Assays: In Vitro, In Vivo
226, Tumor Suppressors
227, Tumor-Neuron Interactions and Neuro-Regulation of Cancer
228, Tumor-induced Immune Suppression
229, Tumorigenesis Drivers
230, Tumorigenesis and Early Microenvironmental Trajectories
231, Tyrosine Kinase, Phosphatase, and Other Inhibitors
232, Vaccine Platforms and Target Identification
233, Vaccines and Other Immunomodulatory Agents
234, Virology and Cancer

Paper Digest Team
New York City, New York, 10017
team@paperdigest.org